Overview
All women from the outpatient department with a history of BC and GSM (genitourinary symptoms of menopause) symptoms will be invited to participate.
After informed consent patients are either randomized to intravaginal laser or hyaluronic acid suppository treatment intravaginally, respectively. Laser treatment will be performed twice, at baseline and after 1 month. The intravaginal hyaluronic acid suppository therapy will be applied daily during the first 10 days and then every third day until the three months follow-up.
At baseline and three months follow-up the following questionnaires will be filled out (VAS, (PGI-I, PGI-S, Female Sexual health questionnaire (EORTC), Baessler questionnaire, EORTC quality of life questionnaire, ZUF-8).
Description
Device I- Laser The laser device is the Juliet feminine laser to treat women with SUI (Stress Urinary Incontinence), GSM and vaginal laxity. Asclepion' s headquarters are located in "Asclepion Laser Technologies GmbH - Brüsseler Str. 10 - 07747 Jena - Germany".
Device II- Suppository The second device is a vaginal suppository called "Cikatridina" manufactured by the company Angelini to treat women with GSM. Angelini Pharma Österreich GmbH's headquarters are located in Brigittenauer Lände 50-54, 1200 Wien, Austria.
Eligibility
Inclusion criteria
- genital symptoms of dryness/ burning/ irritation
- and/ or lack of lubrication during sexual intercourse/ sexual discomfort or pain
- and/or symptoms of urgency and dysuria or recurrent urinary tract infection
- Age 18-80
- History of BC and/ or DCIS
- Completed locoregional therapy
- Current antihormonal therapy for BC possible
- Intravaginal treatment with creams/ suppositories other than study medicationshould be ceased during the trial
Exclusion criteria:
- Current or past genitourinary malignancy
- Abnormal PAP smear
- Current genitourinary tract infection
- Abnormal uterine bleeding
- photosensitive medication